Compare TRVG & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | ENTA |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.6M | 377.5M |
| IPO Year | 2015 | 2012 |
| Metric | TRVG | ENTA |
|---|---|---|
| Price | $6.59 | $12.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $3.95 | ★ $20.40 |
| AVG Volume (30 Days) | 187.7K | ★ 231.6K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $15.59 | $7.76 |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $2.59 | $7.05 |
| 52 Week High | $6.80 | $17.15 |
| Indicator | TRVG | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 40.47 |
| Support Level | $2.76 | $12.19 |
| Resistance Level | N/A | $14.03 |
| Average True Range (ATR) | 0.54 | 0.54 |
| MACD | 0.06 | -0.14 |
| Stochastic Oscillator | 81.65 | 10.33 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.